Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Gellai

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Molecular Pharmacology|February 1, 1988
Oxytocin induces a transient increase in cytosolic free [Ca2+] in renal tubular epithelial cells: evidence for oxytocin receptors on LLC-PK1 cellsF L Stassen, G Heckman, D Schmidt, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 8, 1998
Nonpeptide endothelin receptor antagonists. XI. Pharmacological characterization of SB 234551, a high-affinity and selective nonpeptide ETA receptor antagonistE H Ohlstein, P Nambi, D W Hay, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1994
Nonpeptide endothelin receptor antagonists. III. Effect of SB 209670 and BQ123 on acute renal failure in anesthetized dogsD P Brooks, P D dePalma, M Gellai, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 11, 1992
The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonismE H Ohlstein, M Gellai, D P Brooks, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 1, 1993
Opiate receptors within the blood-brain barrier mediate kappa agonist-induced water diuresisD P Brooks, G Giardina, M Gellai, et al.
Journal of Cardiovascular Pharmacology|May 22, 1998
Pharmacologic characterization of the novel, orally available endothelin-A--selective antagonist SB 247083S A Douglas, P Nambi, M Gellai, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 16, 1994
SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonistE H Ohlstein, P Nambi, S A Douglas, et al.
European Journal of Pharmacology|September 5, 1995
Pharmacology of a potent long-acting imidazole-5-acrylic acid angiotensin AT1 receptor antagonistN Aiyar, E Baker, L Vickery-Clark, et al.
American Journal of Physiology. Renal Physiology|September 1, 2000
Identification of a novel kidney-specific gene downregulated in acute ischemic renal failureE Hu, Z Chen, T Fredrickson, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Molecular Pharmacology|February 1, 1988
Oxytocin induces a transient increase in cytosolic free [Ca2+] in renal tubular epithelial cells: evidence for oxytocin receptors on LLC-PK1 cellsF L Stassen, G Heckman, D Schmidt, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 8, 1998
Nonpeptide endothelin receptor antagonists. XI. Pharmacological characterization of SB 234551, a high-affinity and selective nonpeptide ETA receptor antagonistE H Ohlstein, P Nambi, D W Hay, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1994
Nonpeptide endothelin receptor antagonists. III. Effect of SB 209670 and BQ123 on acute renal failure in anesthetized dogsD P Brooks, P D dePalma, M Gellai, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 11, 1992
The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonismE H Ohlstein, M Gellai, D P Brooks, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 1, 1993
Opiate receptors within the blood-brain barrier mediate kappa agonist-induced water diuresisD P Brooks, G Giardina, M Gellai, et al.
Journal of Cardiovascular Pharmacology|May 22, 1998
Pharmacologic characterization of the novel, orally available endothelin-A--selective antagonist SB 247083S A Douglas, P Nambi, M Gellai, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 16, 1994
SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonistE H Ohlstein, P Nambi, S A Douglas, et al.
European Journal of Pharmacology|September 5, 1995
Pharmacology of a potent long-acting imidazole-5-acrylic acid angiotensin AT1 receptor antagonistN Aiyar, E Baker, L Vickery-Clark, et al.
American Journal of Physiology. Renal Physiology|September 1, 2000
Identification of a novel kidney-specific gene downregulated in acute ischemic renal failureE Hu, Z Chen, T Fredrickson, et al.
Pageof 6